Immune Checkpoint Inhibitors – Access & Reimbursement – Detailed, Expanded Analysis: Multi-indication (US)
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-priced immune checkpoint inhibitors gain label expansions for additional indications, and approvals as part of combinatorial regimens, the high cost associated with these agents will continue to present significant challenges for payers. Developing a clear understanding of prescribing patterns and the reimbursement landscape for immune checkpoint inhibitors is critical to maximize commercial success.
QUESTIONS ANSWERED
- What role do immune checkpoint inhibitors play in the treatment of oncology indications such as NSCLC, malignant melanoma, and bladder cancer?
- What are the key driving forces and constraints that influence MCO reimbursement decisions for immune checkpoint inhibitors?
- Do access and reimbursement challenges for these agents differ by indication?
- How do payers prioritize diminishing budgets and control prescribing of immune checkpoints accordingly?
- What are medical oncologists’ views on select emerging immune checkpoint inhibitors in late-phase development?
GEOGRAPHY: United States.
PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists and 30 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).
KEY DRUGS COVERED: Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, Bavencio.
CONTENT HIGHLIGHTS:
- Actionable recommendations to optimize market access.
- Market access successes and stumbles.
- Reimbursement and contracting.
- Access and prescribing.
- Special topics.
- Opportunities and challenges for emerging therapies.
Table of contents
- Immune Checkpoint Inhibitors - Access & Reimbursement - Detailed, Expanded Analysis: Multi-indication (US)
- Access & Reimbursement Immune Checkpoint Inhibitors US December 2019
Neela Rambaruth, M.Sc., Ph.D., is an analyst on the Oncology team at Clarivate. She has authored content on non-small-cell lung cancer and hepatocellular carcinoma. Previously, she was a postdoctoral scientist at University College London, where she investigated the interaction of novel drugs with a therapeutic receptor involved in cardiovascular disease. She also held a postdoctoral position at Imperial College London, where she studied host-pathogen interaction in tuberculosis. She received her Ph.D. in breast oncology from the University of Westminster. Her doctorate focused on the identification of novel biomarkers associated with metastatic breast cancer. She has also published several peer-reviewed articles on oncology and therapeutic drug discovery.
Chris Lewis is a primary research manager at Clarivate. She is responsible for the coordination, content review, and content generation of U.S. Access & Reimbursement reports, including authoring select A&R reports on managed care trends. Before this position, Ms. Lewis was a senior analyst at HealthLeaders-InterStudy. She analyzed the managed care markets in California, New York, and Pennsylvania. She also launched and authored the Pharmacy Benefit Manager profile series. She received her bachelor’s degree from California State University in Sacramento.
Dana Gheorghe, Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts whose market research spans several oncology indications. Previously, Dr. Gheorghe was a principal analyst and developed extensive expertise forecasting drug markets for a wide range of oncology indications, including breast cancer, non-Hodgkin’s and Hodgkin’s lymphoma, and renal cell carcinoma. Prior to joining the company, she worked as a postdoctoral fellow at Imperial College London and at the Marie Curie Research Institute. She obtained her doctorate from the University of Sheffield and her B.Sc. with honors from the University of Edinburgh.